211 related articles for article (PubMed ID: 33074018)
1. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.
O'Donnell JC; Le TK; Dobrin R; Higashi M; Pereira A; Wagner S; Yang A; Hukkelhoven M
Future Oncol; 2021 Jan; 17(3):333-347. PubMed ID: 33074018
[TBL] [Abstract][Full Text] [Related]
2. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
3. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
4. Use of real-world evidence for oncology clinical decision making in emerging economies.
Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
[TBL] [Abstract][Full Text] [Related]
5. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
Dagenais S; Russo L; Madsen A; Webster J; Becnel L
Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
[TBL] [Abstract][Full Text] [Related]
6. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
[TBL] [Abstract][Full Text] [Related]
7. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
8. Translational hurdles with cannabis medicines.
Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
[TBL] [Abstract][Full Text] [Related]
9. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
10. Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned.
Ro SK; Zhang W; Jiang Q; Li XN; Liu R; Lu CC; Marchenko O; Sun L; Zhao J
Ther Innov Regul Sci; 2023 Jul; 57(4):899-910. PubMed ID: 37179264
[TBL] [Abstract][Full Text] [Related]
11. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
[TBL] [Abstract][Full Text] [Related]
12. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
[TBL] [Abstract][Full Text] [Related]
13. Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective.
Azoulay L
Oncologist; 2022 Sep; 27(9):e731-e738. PubMed ID: 35762676
[TBL] [Abstract][Full Text] [Related]
14. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
[TBL] [Abstract][Full Text] [Related]
15. Examining the Use of Real-World Evidence in the Regulatory Process.
Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH
Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770
[TBL] [Abstract][Full Text] [Related]
16. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
Bloomfield-Clagett B; Rahman M; Smith K; Concato J
Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
[TBL] [Abstract][Full Text] [Related]
17. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
Lau C; Jamali F; Loebenberg R
J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
[TBL] [Abstract][Full Text] [Related]
18. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs.
Zettler ME
Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688
[TBL] [Abstract][Full Text] [Related]
19. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
20. Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.
Serrano P; Hartmann M; Schmitt E; Franco P; Amexis G; Gross J; Mayer-Nicolai C
Clin Pharmacol Ther; 2019 Mar; 105(3):582-597. PubMed ID: 29923615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
